Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. reported that it has requested withdrawal of its Preliminary Proxy Statement on Schedule 14A related to a planned special meeting of stockholders. The company decided not to move forward with those preliminary proxy materials as it continues to evaluate potential strategic transactions.
Wellgistics noted that it may file revised proxy materials at a later date once its review progresses. No definitive proxy materials connected to the withdrawn preliminary proxy statement were mailed or otherwise distributed to stockholders.
Wellgistics Health, Inc. is amending and restating its prior proxy to convert a scheduled special meeting into its 2026 annual meeting to be held virtually on June 19, 2026 and to present multiple governance and capital-structure proposals for stockholder approval.
The proposals include a name change to Vantix Health Inc., authorization of 10,000,000 shares of blank-check preferred stock, an amendment to the Equity Incentive Plan to add 56,493,936 shares and reserve an additional 100,000 super-voting preferred shares, approval to designate and issue a one-for-one convertible preferred series, approval to issue a new super-voting preferred series to certain directors and officers, and approval under Nasdaq rules to permit future issuances that could exceed 19.99% of outstanding common stock under certain circumstances. The record date for voting is April 22, 2026, with 126,653,372 shares outstanding as of that date.
Wellgistics Health, Inc., through its subsidiary Wellgistics, LLC, entered into an Acknowledgment of Indebtedness, Forbearance and Repayment Agreement with Marco Capital, Inc. on May 1, 2026. Wellgistics acknowledged approximately $1.77 million in outstanding obligations under a prior Loan and Security Agreement.
Under the Forbearance Agreement, Marco Capital agreed to temporarily forbear from exercising certain rights and remedies through June 15, 2026. Wellgistics must make bi-weekly payments of $50,000 starting May 5, 2026, and a portion of net proceeds from future financings during the forbearance period may need to be applied to repayment. The obligations will accrue interest at a rate equal to Term SOFR plus 11.5% per annum beginning May 5, 2026.
Wellgistics Health, Inc. filed an amended current report to correct the cover-page report date to February 9, 2026 and to restate its description of a key contract. The company explains that the material definitive agreement for disclosure purposes is an Amended Settlement Agreement entered on February 9, 2026 with Silverback Capital Corporation, which modifies an earlier settlement agreement referenced in the original report. All other disclosures from the original report remain unchanged.
Wellgistics Health, Inc. is asking stockholders at a virtual special meeting on May 21, 2026 to approve three charter and plan changes. The company seeks to change its name to Vantix Health Inc., add authorization for 10,000,000 shares of blank check preferred stock, and significantly expand its 2023 Equity Incentive Plan.
The equity plan would rise from 43,506,064 to 100,000,000 shares reserved, an increase of 56,493,936 shares, described as about 45% of common shares outstanding as of April 22, 2026. The plan’s automatic annual increase limit would also move from 3% to up to 10% of shares outstanding, at the administrator’s discretion. The board unanimously recommends voting “FOR” all three proposals.
Wellgistics Health, Inc. filed Amendment No. 1 to its annual report to update governance and ownership information. The amendment restates the sections on directors, executive officers and beneficial ownership and adds exhibits, including the company’s compensation recovery (clawback) policy.
The filing details a refreshed leadership team, including President Prashant Patel, Interim Chief Financial Officer Eric Sherb, and Chairman Suren Ajjarapu, along with three independent directors. It also describes the audit and nominating/compensation committees and confirms that Gary Herman is the audit committee financial expert.
The amendment provides a detailed beneficial ownership table as of March 2, 2026, showing significant holdings by insiders and one additional holder over 5%. It also summarizes the company’s code of ethics and insider trading policy, including blackout periods and a prohibition on short sales by employees, officers and directors.
Wellgistics Health, Inc. is asking stockholders to approve three amendments at a virtual Special Meeting on May 21, 2026: a corporate name change to Vantix Health Inc., authorization of 10,000,000 shares of blank‑check preferred stock, and an amendment to its 2023 Equity Incentive Plan to add 56,493,936 shares and change the annual automatic increase to up to 10% of outstanding shares beginning January 1, 2027.
The record date for voting is April 22, 2026, when 126,653,372 shares were outstanding. The Board recommends voting FOR all proposals; each approval requires the affirmative vote of a majority of outstanding common stock.
Wellgistics Health, Inc. reported that Chief Executive Officer Prashant Patel received significant equity compensation. On March 31, 2026, he was granted 5,000,000 shares of common stock at a stated value of $0.20 per share, increasing his direct holdings to 9,118,247 shares.
On the same date, he also received 5,000,000 warrants to purchase common stock with a $0.01 exercise price, expiring on March 31, 2031. The filing notes both the shares and warrants were issued as compensation for his service in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.